Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tal Freund

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Clinical and Experimental Immunology|May 20, 2024
Cellular immune response to the anti-SARS-CoV-2 BNT162b2 mRNA vaccine in pediatric autoimmune inflammatory rheumatic disease patients and controlsTali Eviatar, Adi Pappo, Tal Freund, et al.
The Journal of Allergy and Clinical Immunology|June 4, 2021
Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunityDavid Hagin, Tal Freund, Michal Navon, et al.
Human Genetics|March 22, 2022
CD55-deficiency in Jews of Bukharan descent is caused by the Cromer blood type Dr(a-) variantAlina Kurolap, David Hagin, Tal Freund, et al.
Bone Marrow Transplantation|November 24, 2020
Anti-CD19 CAR-T therapy for EBV-negative posttransplantation lymphoproliferative disease-a single center case seriesEfrat Luttwak, David Hagin, Chava Perry, et al.
Journal of Clinical Immunology|July 16, 2020
Novel NCF2 Mutation Causing Chronic Granulomatous DiseaseIdit Lachover Roth, Pazit Salamon, Tal Freund, et al.
Open Forum Infectious Diseases|August 4, 2023
Humoral and Cellular Immune Responses of People Living With Human Immunodeficiency Virus After 3 Doses of Messenger RNA BNT162b2 Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine: A Prospective Cohort StudyLuba Tau, David Hagin, Tal Freund, et al.
Transplantation and Cellular Therapy|February 19, 2022
Immunogenicity of a Third Dose of the BNT162b2 mRNA Covid-19 Vaccine in Patients with Impaired B Cell Reconstitution After Cellular Therapy-A Single Center Prospective Cohort StudyRon Ram, Tal Freund, Tami Halperin, et al.
Open Forum Infectious Diseases|March 31, 2022
SARS-CoV-2 Humoral and Cellular Immune Responses of Patients With HIV After Vaccination With BNT162b2 mRNA COVID-19 Vaccine in the Tel-Aviv Medical CenterLuba Tau, Dan Turner, Amos Adler, et al.
Experimental Dermatology|January 14, 2026
Defective Function of Inhibitor of κB Kinase Subunit Beta Associated With Multiple Immune-Mediated DisordersKiril Malovitski, Noy Keller Rosenthal, Lubna Khair, et al.
Frontiers in Immunology|January 6, 2023
Dominant-negative signal transducer and activator of transcription (STAT)3 variants in adult patients: A single center experienceOded Shamriz, Limor Rubin, Amos J Simon, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Clinical and Experimental Immunology|May 20, 2024
Cellular immune response to the anti-SARS-CoV-2 BNT162b2 mRNA vaccine in pediatric autoimmune inflammatory rheumatic disease patients and controlsTali Eviatar, Adi Pappo, Tal Freund, et al.
The Journal of Allergy and Clinical Immunology|June 4, 2021
Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunityDavid Hagin, Tal Freund, Michal Navon, et al.
Human Genetics|March 22, 2022
CD55-deficiency in Jews of Bukharan descent is caused by the Cromer blood type Dr(a-) variantAlina Kurolap, David Hagin, Tal Freund, et al.
Bone Marrow Transplantation|November 24, 2020
Anti-CD19 CAR-T therapy for EBV-negative posttransplantation lymphoproliferative disease-a single center case seriesEfrat Luttwak, David Hagin, Chava Perry, et al.
Journal of Clinical Immunology|July 16, 2020
Novel NCF2 Mutation Causing Chronic Granulomatous DiseaseIdit Lachover Roth, Pazit Salamon, Tal Freund, et al.
Open Forum Infectious Diseases|August 4, 2023
Humoral and Cellular Immune Responses of People Living With Human Immunodeficiency Virus After 3 Doses of Messenger RNA BNT162b2 Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine: A Prospective Cohort StudyLuba Tau, David Hagin, Tal Freund, et al.
Transplantation and Cellular Therapy|February 19, 2022
Immunogenicity of a Third Dose of the BNT162b2 mRNA Covid-19 Vaccine in Patients with Impaired B Cell Reconstitution After Cellular Therapy-A Single Center Prospective Cohort StudyRon Ram, Tal Freund, Tami Halperin, et al.
Open Forum Infectious Diseases|March 31, 2022
SARS-CoV-2 Humoral and Cellular Immune Responses of Patients With HIV After Vaccination With BNT162b2 mRNA COVID-19 Vaccine in the Tel-Aviv Medical CenterLuba Tau, Dan Turner, Amos Adler, et al.
Experimental Dermatology|January 14, 2026
Defective Function of Inhibitor of κB Kinase Subunit Beta Associated With Multiple Immune-Mediated DisordersKiril Malovitski, Noy Keller Rosenthal, Lubna Khair, et al.
Frontiers in Immunology|January 6, 2023
Dominant-negative signal transducer and activator of transcription (STAT)3 variants in adult patients: A single center experienceOded Shamriz, Limor Rubin, Amos J Simon, et al.
Pageof 2